What happened in optometry this week: March 25 - March 29
Catch up on what happened in optometry during the week of March 25-March 29.
Catch up with what Optometry Times shared this week:
First Canadian participant dosed in Phase 1/2 ABA-1, CLARA clinical trial of AURN001
By Jordana Joy, Associate Editor
Aurion Biotech has announced the dosing of the first Canadian participants in its Phase 1/2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. The trial’s primary endpoint is the percentage of participants, who have corneal edema secondary to corneal endothelial dysfunction, who gain 3 lines of vision in 6 months, according to a news release.
Vision loss's role in accessibility advocacy with Rebecca Alexander
By Rebecca Alexander, LCSW-R, MPH and Jordana Joy, Associate Editor
For Rebecca Alexander, LCSW-R, MPH, every daily task day is impacted by the effects of Usher syndrome. Having completely lost her hearing and with only 5 to 10 degrees of central vision, Alexander said walking into a doctor's office that practices accessibility for those who are blind or low vision makes a world of a difference. She chats about living with Usher syndrome and her work as a disability rights advocate and psychodynamic psychotherapist in an exclusive Optometry Times interview.
Study shows minocycline has no benefit in slowing, preventing GA expansion in patients with dry AMD
By Martin David Harp, Associate Editor, Ophthalmology Times
A recent study on minocycline showed that the drug has no benefit in preventing or slowing vision loss related to geographic atrophy (GA) expansion in people with dry age-related macular degeneration (AMD).1
ARxVision, Seeing AI, NaviLens team up for pilot headset program
By Jordana Joy, Associate Editor
A new pilot program has launched in part of collaborative efforts between ARxVision, Microsoft’s Seeing AI app and the NaviLens app. This new program integrates the Android version of these apps with the ARx Gen 1.5 wearable headset, which describes the visual world by transmitting audio via bone conduction speakers.1
Secondary analysis suggests DED severity, systemic medication use correlation
By Jordana Joy, Associate Editor
A secondary analysis drawn from data collected from the DRy Eye Assessment and Management (DREAM) Study found an association between systemic medication use and an increase in severity of dry eye disease (DED). Of the medications evaluated, worse DED signs and symptoms were found in corticosteroid, antihistamines, aspirin, vitamin D3, and medications for seizure users compared to non-users, of which users of corticosteroids had multiple worse and more consistent DED signs.1
